Advocacy intelligence hub — real-time data for patient organizations
University of Wisconsin, Madison — PHASE1, PHASE2
Seattle Children's Hospital — PHASE1
Riboscience, LLC. — PHASE2
Hong Wu — NA
AstraZeneca — PHASE1
Bristol-Myers Squibb — PHASE1, PHASE2
Asan Medical Center — PHASE2
Beijing Biotech — PHASE1, PHASE2
Tongji Hospital — PHASE2
Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
Patient Assistance Programs2
IMFINZI
AstraZeneca Pharmaceuticals LP
Stivarga
Bayer HealthCare Pharmaceuticals, Inc.
IMFINZI
(durvalumab)Orphan drugAstraZeneca Pharmaceuticals LP
Programmed Death Ligand-1 Blocker [EPC]
12.1 Mechanism of Action Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expr...
Imjudo
(tremelimumab-actl)Orphan drugAstraZeneca Pharmaceuticals LP
CTLA-4-directed Blocking Antibody [EPC]
12.1 Mechanism of Action CTLA-4 is a negative regulator of T-cell activity. Tremelimumab-actl is a monoclonal antibody that binds to CTLA-4 and blocks...
Tecentriq and Avastin
(atezolizumab + bevacizumab)Orphan drugGenentech, Inc.
LENVIMA
(lenvatinib)Orphan drugEisai Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors V...
Stivarga
(regorafenib)Orphan drugBayer HealthCare Pharmaceuticals, Inc.
12.1 Mechanism of Action Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular fu...
Nexavar
(sorafenib)Orphan drugstandardBayer HealthCare Pharmaceuticals, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple int...
Chao Liu, PHD
Shenzhen Hemogen
Jeong Min Lee, MD
Seoul National University Hospital
Hong Jae Chon, MS, DDS
Principal Investigator
📍 BLOOMINGDALE, IL
Mark Yarchoan, MD, M.D
Johns Hopkins Medical Institution
📍 BALTIMORE, MD
Ghassan Abou-Alfa, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Pei Wang, PhD
Eureka Therapeutics Inc.